Promis Dx Presents Validation Data for Urine DNA Test for Bladder Cancer Detection in Hematuria - PRNewswire
PASADENA, Calif. , Sept. 10, 2021 /PRNewswire/ -- Promis Diagnostics, Inc., a molecular diagnostics company focused on early cancer diagnosis, recently presented clinical validation data for CystoChek, its proprietary urine-based DNA methylation test of PENK for bladder cancer (BCa) detection in hematuria, at the 2021 American Urological Association (AUA) Annual Meeting. Researchers from Genomictree Inc, Chungnam National University Hospital (Daejeon, South Korea ), and Promis previously discovered that aberrant methylation of PENK, a potential biomarker, frequently occurs in bladder cancer. To further demonstrate the validity of their discovery, and to evaluate the performance of CystoChek, two separate clinical studies were conducted. First, in a retrospective study, the data showed a sensitivity of 91.0% with a specificity of 93.5% in detecting Ta high-grade and greater stages of BCa in 567 hematuria patients. Second, in a prospective study, the data demonstrated a sens...